RNA processing modification mediated subtypes illustrate the distinctive features of tumor microenvironment in hepatocellular carcinoma

被引:0
作者
Li, Xinhui [1 ]
Liu, Shan [1 ]
Zou, Laibin [2 ]
Dai, Min [3 ]
Zhu, Chaobei [4 ]
机构
[1] Hubei Univ Med, Renmin Hosp, Dept Oncol, Shiyan 442000, Hubei, Peoples R China
[2] Southern Med Univ, Sch Clin Med 3, Dept Hepatobiliary & Pancreat Surg, Huadu Dist Peoples Hosp Guangzhou, Guangzhou 510800, Peoples R China
[3] Sun Yet sen Univ, affiliated Hosp 3, Dept Tradit Chinese Med & Allergy, Guangzhou 510800, Peoples R China
[4] Hubei Univ Med, Renmin Hosp, Dept Gastroenterol, Shiyan 442000, Hubei, Peoples R China
关键词
D O I
10.1038/s41435-024-00265-8
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Multiple transcript isoforms of genes can be formed by processing and modifying the 5 ' and 3 ' ends of RNA. Herein, the aim of this study is to uncover the characteristics of RNA processing modification (RPM) in hepatocellular carcinoma (HCC), and to identify novel biomarkers and potential targets for treatment. Firstly, integrated bioinformatics analysis was carried out to identify risk prognostic RPM regulators (RPMRs). Then, we used these RPMRs to identify subtypes of HCC and explore differences in immune microenvironment and cellular function improvement pathways between the sub-types. Finally, we used the principal component analysis algorithms to estimate RPMscore, which were applied to 5 cohorts. Lower RPMscore among patients correlated with a declined survival rate, increased immune infiltration, and raised expression of immune checkpoints, aligning with the "immunity tidal model theory". The RPMscore exhibited robust, which was validated in multiple datasets. Mechanistically, low RPMscore can create an immunosuppressive microenvironment in HCC by manipulating tumor-associated macrophages. Preclinically, patients with high RPMscore might benefit from immunotherapy. The RPMscore is helpful in clustering HCC patients with distinct prognosis and immunotherapy. Our RPMscore model can help clinicians to select personalized therapy for HCC patients, and RPMscore may act a part in the development of HCC.
引用
收藏
页码:132 / 148
页数:17
相关论文
共 38 条
  • [1] xCell: digitally portraying the tissue cellular heterogeneity landscape
    Aran, Dvir
    Hu, Zicheng
    Butte, Atul J.
    [J]. GENOME BIOLOGY, 2017, 18
  • [2] Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
    Ayuso, Carmen
    Rimola, Jordi
    Vilana, Ramon
    Burrel, Marta
    Darnell, Anna
    Garcia-Criado, Angeles
    Bianchi, Luis
    Belmonte, Ernest
    Caparroz, Carla
    Barrufet, Marta
    Bruix, Jordi
    Bru, Concepcion
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2018, 101 : 72 - 81
  • [3] SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma
    Chen, Qianping
    Zheng, Wang
    Guan, Jian
    Liu, Hongxia
    Dan, Yao
    Zhu, Lin
    Song, Yimeng
    Zhou, Yuchuan
    Zhao, Xinrui
    Zhang, Yuhong
    Bai, Yang
    Pan, Yan
    Zhang, Jianghong
    Shao, Chunlin
    [J]. CELL DEATH AND DIFFERENTIATION, 2023, 30 (01) : 137 - 151
  • [4] Cleavage and Polyadenylation Specific Factor 1 Promotes Tumor Progression via Alternative Polyadenylation and Splicing in Hepatocellular Carcinoma
    Chen, Shi-lu
    Zhu, Zhong-xu
    Yang, Xia
    Liu, Li-li
    He, Yang-fan
    Yang, Ming-ming
    Guan, Xin-yuan
    Wang, Xin
    Yun, Jing-ping
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [5] Quantifying tumor-infiltrating immune cells from transcriptomics data
    Finotello, Francesca
    Trajanoski, Zlatko
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) : 1031 - 1040
  • [6] Alternative cleavage and polyadenylation in health and disease
    Gruber, Andreas J.
    Zavolan, Mihaela
    [J]. NATURE REVIEWS GENETICS, 2019, 20 (10) : 599 - 614
  • [7] HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events
    Jiang, Ning
    Yu, Yue
    Wu, Dawei
    Wang, Shuhang
    Fang, Yuan
    Miao, Huilei
    Ma, Peiwen
    Huang, Huiyao
    Zhang, Min
    Zhang, Yu
    Tang, Yu
    Li, Ning
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 737 - 747
  • [8] Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
    Jiang, Yao
    Hong, Kai
    Zhao, Yingchao
    Xu, Kai
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Andrographolide causes p53-independent HCC cell death through p62 accumulation and impaired DNA damage repair
    Li, Xin-Yu
    Cui, Xuan
    Xie, Chang-Quan
    Wu, Yong
    Song, Tang
    He, Jin-Di
    Feng, Ji
    Cui, Qian-Ru
    Bin, Jin-Lian
    Li, Qiu-Yun
    Xiao, Cheng
    Deng, Jing-Huan
    Lu, Guo-Dong
    Zhou, Jing
    [J]. PHYTOMEDICINE, 2023, 121
  • [10] Immunotherapies for hepatocellular carcinoma
    Llovet, Josep M.
    Castet, Florian
    Heikenwalder, Mathias
    Maini, Mala K.
    Mazzaferro, Vincenzo
    Pinato, David J.
    Pikarsky, Eli
    Zhu, Andrew X.
    Finn, Richard S.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (03) : 151 - 172